Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
04/18/20184:01PMPRNUSNeurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting New Data Evaluating Efficacy of INGREZZA Across Body Regions in Patients with Tardive Dyskinesia Data from KINECT 4 Study Demonstrate Long-Term Efficacy and Tolerability in Patients with Tardive Dyskinesia... More...>>
04/10/20188:15AMPRNUSAbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain - FDA requires extended time for review of additional information in New Drug Application (NDA) - Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date - Based... More...>>
03/07/20181:15PMPRNUSNeurocrine Biosciences to Present at Upcoming Healthcare Conferences
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire SAN DIEGO, March 7, 2018 SAN DIEGO, March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences, will present at the following investor conferences: Cowen and Company... More...>>
02/21/20188:00AMPRNUSAbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroi...
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids − First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced... More...>>
02/14/20184:01PMPRNUSNeurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinica...
Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data Neurocrine Plans to File the NDA During the First Half of 2019 PR Newswire SAN DIEGO, Feb. 14, 2018 SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX... More...>>
02/13/20184:01PMPRNUSNeurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch... More...>>
02/08/20181:15PMPRNUSNeurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference Live Audio Webcast Will be on February 15, 2018 PR Newswire SAN DIEGO, Feb. 8, 2018 SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7th Annual Global... More...>>
02/06/20181:15PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results Conference Call and Webcast Scheduled for Tuesday, February 13 PR Newswire SAN DIEGO, Feb. 6, 2018 SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that... More...>>
01/07/20181:01PMPRNUSNeurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief ...
Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer PR Newswire SAN DIEGO, Jan. 7, 2018 SAN DIEGO, Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine... More...>>
01/07/20181:00PMPRNUSNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones - Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017 - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales... More...>>
01/02/20184:01PMPRNUSNeurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference Live Audio Webcast Will be on January 8, 2018 PR Newswire SAN DIEGO, Jan. 2, 2018 SAN DIEGO, Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference... More...>>
12/14/20174:15PMBWPuma Biotechnology Added to NASDAQ Biotechnology Index
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market® (NASDAQ) that meet NBI’s eligibility criteria... More...>>
12/07/20171:15PMPRNUSNeurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Live Audio Webcast Will be on December 14, 2017 PR Newswire SAN DIEGO, Dec. 7, 2017 SAN DIEGO, Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets... More...>>
12/04/20174:01PMPRNUSNeurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Imp...
Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms - INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial - Additional... More...>>
11/29/20174:01PMPRNUSNeurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the Ame...
Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic PR Newswire SAN DIEGO, Nov. 29, 2017 SAN DIEGO, Nov... More...>>
11/21/20171:15PMPRNUSNeurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference Live Audio Webcast Will be on November 28, 2017 PR Newswire SAN DIEGO, Nov. 21, 2017 SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference... More...>>
11/21/20178:15AMGLOBEDetailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrin...
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nexstar Broadcasting Group, Inc. (NASDAQ:NXST), CECO Environmental Corp. (NASDAQ:CECE), Performance Food... More...>>
11/20/20174:01PMPRNUSNeurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer PR Newswire SAN DIEGO, Nov. 20, 2017 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining... More...>>
11/14/20171:34PMPRNUSNeurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in...
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry - Data from the KINECT 3 Phase III Extension Study Show INGREZZA (valbenazine) Maintained Improvement with Favorable Safety Profile in 52-week Trial PR Newswire... More...>>
11/09/20174:01PMPRNUSINGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Awar...
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association PR Newswire SAN DIEGO, Nov. 9, 2017 SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20180420 14:22:22